All In Biotech

Drug Trial Radar · NCT05996003

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Feb 26, 2027

Study completion Feb 26, 2027

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.

Conditions

  • Duchenne Muscular Dystrophy
  • Exon 44
  • DMD

Interventions

  • NS-089/NCNP-02Drug

    Cohort 1: Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1 Cohort 2: Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event and Adverse Drug ReactionTime frame: through study completion, up to follow-up phone call for Part 2
  2. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Maximum plasma concentration (Cmax) of NS-089/NCNP-02
  3. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Time of the maximum plasma concentration (Tmax) of NS-089/NCNP-02
  4. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Terminal half-life (T1/2) of NS-089/NCNP-02
  5. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to the last time point (AUC0-t) of NS-089/NCNP-02
  6. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to infinity (AUC0-∞) of NS-089/NCNP-02
  7. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Total body clearance (CLtot) of NS-089/NCNP-02
  8. Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] The volume in the terminal state (Vz) of NS-089/NCNP-02
  9. Urine pharmacokinetic parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Urinary excretion of NS-089/NCNP-02
  10. Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot).Time frame: Baseline, Week25

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rare Disease Research

    Atlanta, Georgia

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Kansas Medical Center (KUMC)

    Kansas City, Kansas

  • Boston Children's Hospital

    Boston, Massachusetts

  • Columbia University Pediatric Neuromuscular Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • The Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania

  • UT Southwestern/Children's Health

    Dallas, Texas

  • Virginia Commonwealth University Health System

    Richmond, Virginia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Fukui Prefectural Hospital

    Fukui-shi, Fukui, Japan

  • National Hospital Organization Nagara Medical Center

    Nagara, Gifu-shi, Gifu, Japan

  • NHO Osaka Toneyama Medical Center

    Toyonaka, Osaka, Japan

  • Shiga General Hospital

    Moriyama-shi, Shiga, Japan

  • National Center of Neurology and Psychiatry

    Kodaira, Tokyo, Japan

  • Starship Children's Hospital

    Auckland, New Zealand

  • Seoul National University Hospital

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam, South Korea

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye)

  • Istanbul University- Istanbul Faculty of Medicine

    Istanbul, Turkey (Türkiye)

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey (Türkiye)

  • S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.